Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by westcoast1000on Feb 07, 2023 4:19pm
245 Views
Post# 35272850

Adlai Nortye impact

Adlai Nortye impact There has been a lot of discussion about AN and the implications of a possible buy-out.

If I recall correctly, AN was started in part with a lot of Chinese government capital. One of the senior VPs bio says Mr. Yang is a member of the 12th CPPCC in Yuhang District, Hangzhou. The CPPCC is the Chinese communist party citizen advisory committee, roughly speaking, which is tied tightly to the party. 

More broadly, I have a close friend who is a globally noted scholar on China and Chinese law. He indicated to me previously that no notable Chinese company operates independently of the Chinese com munist party. That is widely known and globally understood. Carsten Lu the founder of AN, is a young guy, trained in China, who was probably selected to start a pharma company on behalf of the party and the country. Look no further than Huawei to see an example in the computer world. 

The upshot is that if ONCY or Pfizer or Roche want to sell pharma into China it is always going to be in partnership with a company led by someone connected to the party at a high level. So this arrangement is a good one for Oncy or whoever hopes to make sales in China.

As for whether ONCY features as a partner on their web site, it could be the partnerships are listed in terms of current revenues, or costs paid already, or prestige, or any of a number of reasons. That does not mean they do not care about pela.

All in my opinion.
<< Previous
Bullboard Posts
Next >>